Literature DB >> 32001514

Language and spatial dysfunction in Alzheimer disease with white matter thorn-shaped astrocytes.

Elisa de Paula França Resende1, Amber L Nolan1, Cathrine Petersen1, Alexander J Ehrenberg1, Salvatore Spina1, Isabel E Allen1, Howard J Rosen1, Joel Kramer1, Bruce L Miller1, William W Seeley1, Maria Luiza Gorno-Tempini1, Zachary Miller1, Lea T Grinberg2.   

Abstract

OBJECTIVES: Alzheimer disease (AD) shows a broad array of clinical presentations, but the mechanisms underlying these phenotypic variants remain elusive. Aging-related astrogliopathy (ARTAG) is a relatively recent term encompassing a broad array of tau deposition in astroglia outside the range of traditional tauopathies. White matter thorn-shaped astrocyte (WM-TSA) clusters, a specific ARTAG subtype, has been associated with atypical language presentation of AD in a small study lacking replication. To interrogate the impact of WM-TSA in modifying clinical phenotype in AD, we investigated a clinicopathologic sample of 83 persons with pure cortical AD pathology and heterogeneous clinical presentations.
METHODS: We mapped WM-TSA presence and density throughout cortical areas and interrogated whether WM-TSA correlated with atypical AD presentation or worse performance in neuropsychological testing.
RESULTS: WM-TSA was present in nearly half of the cases and equally distributed in typical and atypical AD presentations. Worsening language and visuospatial functions were correlated with higher WM-TSA density in language-related and visuospatial-related regions, respectively. These findings were unrelated to regional neurofibrillary tangle burden. Next, unsupervised clustering divided the participants into 2 groups: a high-WM-TSA (n = 9) and low-WM-TSA (n = 74) pathology signature. The high-WM-TSA group scored significantly worse in language but not in other cognitive domains.
CONCLUSIONS: The negative impact of WM-TSA pathology to language and possibly visuospatial networks suggests that WM-TSA is not as benign as other ARTAG types and may be explored as a framework to understand the mechanisms and impact of astrocytic tau deposition in AD in humans.
© 2020 American Academy of Neurology.

Entities:  

Mesh:

Year:  2020        PMID: 32001514      PMCID: PMC7274917          DOI: 10.1212/WNL.0000000000008937

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  48 in total

1.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

Authors:  Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

3.  Typical and atypical pathology in primary progressive aphasia variants.

Authors:  Edoardo G Spinelli; Maria Luisa Mandelli; Zachary A Miller; Miguel A Santos-Santos; Stephen M Wilson; Federica Agosta; Lea T Grinberg; Eric J Huang; John Q Trojanowski; Marita Meyer; Maya L Henry; Giancarlo Comi; Gil Rabinovici; Howard J Rosen; Massimo Filippi; Bruce L Miller; William W Seeley; Maria Luisa Gorno-Tempini
Journal:  Ann Neurol       Date:  2017-03-20       Impact factor: 10.422

4.  Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia.

Authors:  Tamar Gefen; Katherine Gasho; Alfred Rademaker; Mona Lalehzari; Sandra Weintraub; Emily Rogalski; Christina Wieneke; Eileen Bigio; Changiz Geula; M-Marsel Mesulam
Journal:  Brain       Date:  2012-04-19       Impact factor: 13.501

5.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

6.  Characterization of thorn-shaped astrocytes in white matter of temporal lobe in Alzheimer's disease brains.

Authors:  Irene López-González; Margarita Carmona; Rosa Blanco; José Luna-Muñoz; Alejandra Martínez-Mandonado; Raúl Mena; Isidre Ferrer
Journal:  Brain Pathol       Date:  2012-09-13       Impact factor: 6.508

7.  Criteria for the diagnosis of corticobasal degeneration.

Authors:  Melissa J Armstrong; Irene Litvan; Anthony E Lang; Thomas H Bak; Kailash P Bhatia; Barbara Borroni; Adam L Boxer; Dennis W Dickson; Murray Grossman; Mark Hallett; Keith A Josephs; Andrew Kertesz; Suzee E Lee; Bruce L Miller; Stephen G Reich; David E Riley; Eduardo Tolosa; Alexander I Tröster; Marie Vidailhet; William J Weiner
Journal:  Neurology       Date:  2013-01-29       Impact factor: 9.910

8.  TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features.

Authors:  Keith A Josephs; Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Melissa E Murray; Amanda M Liesinger; Leonard Petrucelli; Matthew L Senjem; Robert J Ivnik; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson
Journal:  Ann Neurol       Date:  2015-09-16       Impact factor: 10.422

9.  Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation.

Authors:  Marc Teichmann; Aurélie Kas; Claire Boutet; Sophie Ferrieux; Marie Nogues; Dalila Samri; Christina Rogan; Didier Dormont; Bruno Dubois; Raffaella Migliaccio
Journal:  Brain       Date:  2013-10-08       Impact factor: 13.501

10.  Is Alzheimer's disease a homogeneous disease entity?

Authors:  Amos D Korczyn
Journal:  J Neural Transm (Vienna)       Date:  2013-08-11       Impact factor: 3.575

View more
  5 in total

1.  Relationships among tau burden, atrophy, age, and naming in the aphasic variant of Alzheimer's disease.

Authors:  Adam Martersteck; Jaiashre Sridhar; Christina Coventry; Sandra Weintraub; M-Marsel Mesulam; Emily Rogalski
Journal:  Alzheimers Dement       Date:  2021-09-08       Impact factor: 21.566

Review 2.  New insights into atypical Alzheimer's disease in the era of biomarkers.

Authors:  Jonathan Graff-Radford; Keir X X Yong; Liana G Apostolova; Femke H Bouwman; Maria Carrillo; Bradford C Dickerson; Gil D Rabinovici; Jonathan M Schott; David T Jones; Melissa E Murray
Journal:  Lancet Neurol       Date:  2021-03       Impact factor: 44.182

Review 3.  Astroglia and Tau: New Perspectives.

Authors:  Gabor G Kovacs
Journal:  Front Aging Neurosci       Date:  2020-04-09       Impact factor: 5.750

Review 4.  Space-occupying brain lesions, trauma-related tau astrogliopathy, and ARTAG: a report of two cases and a literature review.

Authors:  Adam D Bachstetter; Filip G Garrett; Gregory A Jicha; Peter T Nelson
Journal:  Acta Neuropathol Commun       Date:  2021-03-23       Impact factor: 7.801

5.  DHCR24 Knockdown Induces Tau Hyperphosphorylation at Thr181, Ser199, Ser262, and Ser396 Sites via Activation of the Lipid Raft-Dependent Ras/MEK/ERK Signaling Pathway in C8D1A Astrocytes.

Authors:  Meiting Mai; Xiaorou Guo; Yue Huang; Wenbin Zhang; Yixuan Xu; Ying Zhang; Xiaojing Bai; Junfeng Wu; Hengbing Zu
Journal:  Mol Neurobiol       Date:  2022-07-08       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.